The burgeoning landscape of emerging treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a comparable https://orlandocear335372.diowebhost.com/93839592/retatrutide-vs-tirzepatide-a-comparative-analysis